 Management to Discuss Pipeline Goals and Development Strategies across four Preclinical and 2 Clinical Programs across Multiple Central Nervous System CNS Disorders NLS to Webcast its RD Day Event Tuesday, January 31 at 10:00am EST ZURICH, SWITZERLAND ACCESSWIRE January 12, 2023 NLS Pharmaceutics Ltd. Nasdaq:NLSP, NLSPW NLS or the Company, a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced plans to showcase its global strategic RD progress and platform, as well as its product candidate and pipeline goals for 2023, with a focus on rare and complex CNS disorders with unmet medical needs. 